Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Supplement 1

Milnacipran: a unique antidepressant?

Authors Siegfried Kasper, Gerald Pail

Published Date August 2010 Volume 2010:6(Supplement 1) Pages 23—31

DOI http://dx.doi.org/10.2147/NDT.S11777

Published 25 August 2010

Siegfried Kasper, Gerald Pail
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria

Abstract: Tricyclic antidepressants (TCAs) are among the most effective antidepressants available, although their poor tolerance at usual recommended doses and toxicity in ­overdose make them difficult to use. While selective serotonin reuptake inhibitors (SSRIs) are ­better tolerated than TCAs, they have their own specific problems, such as the aggravation of sexual dysfunction, interaction with coadministered drugs, and for many, a discontinuation syndrome. In addition, some of them appear to be less effective than TCAs in more severely depressed patients. Increasing evidence of the importance of norepinephrine in the etiology of depression has led to the development of a new generation of antidepressants, the serotonin and ­norepinephrine reuptake inhibitors (SNRIs). Milnacipran, one of the pioneer SNRIs, was designed from theoretic considerations to be more effective than SSRIs and better tolerated than TCAs, and with a simple pharmacokinetic profile. Milnacipran has the most balanced potency ratio for reuptake inhibition of the two neurotransmitters compared with other SNRIs (1:1.6 for milnacipran, 1:10 for duloxetine, and 1:30 for venlafaxine), and in some studies milnacipran has been shown to inhibit norepinephrine uptake with greater potency than serotonin (2.2:1). Clinical studies have shown that milnacipran has efficacy comparable with the TCAs and is superior to SSRIs in severe depression. In addition, milnacipran is well tolerated, with a low potential for pharmacokinetic drug–drug interactions. Milnacipran is a first-line therapy suitable for most depressed patients. It is frequently successful when other treatments fail for reasons of efficacy or tolerability.

Keywords: milnacipran, SNRI, antidepressant efficacy, tolerability

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Choking risk among psychiatric inpatients

Nagamine T

Neuropsychiatric Disease and Treatment 2011, 7:381-382

Published Date: 20 June 2011

The noradrenergic symptom cluster: clinical expression and neuropharmacology

Blier P, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:15-20

Published Date: 3 June 2011

Noradrenergic symptom cluster in depression

Montgomery S, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:1-2

Published Date: 31 May 2011

The increasing burden of depression

Lépine J-P, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:3-7

Published Date: 31 May 2011

The importance of norepinephrine in depression

Moret C, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:9-13

Published Date: 31 May 2011

Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Kasper S, Meshkat D, Kutzelnigg A

Neuropsychiatric Disease and Treatment 2011, 7:21-27

Published Date: 31 May 2011

Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities

Miho Takenoshita, Tomoko Sato, Yuichi Kato, et al

Neuropsychiatric Disease and Treatment 2010, 6:699-705

Published Date: 13 October 2010

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

Mike Briley, Chantal Moret

Neuropsychiatric Disease and Treatment 2010, 6:647-655

Published Date: 23 September 2010

Treatment of patients with comorbid depression and diabetes with metformin and milnacipran

Peter Hofmann

Neuropsychiatric Disease and Treatment 2010, 6:9-15

Published Date: 25 August 2010

Antidepressant therapy with milnacipran and venlafaxine

Lucilla Mansuy

Neuropsychiatric Disease and Treatment 2010, 6:17-22

Published Date: 25 August 2010

Milnacipran: recent findings in depression

Guest editors: Stuart Montgomery (London, UK) and Mike Briley (Castres, France)

Neuropsychiatric Disease and Treatment 2010, 6:0-0

Published Date: 24 August 2010

Editorial Foreword - Milnacipran: recent findings in depression

Stuart Montgomery, Mike Briley

Neuropsychiatric Disease and Treatment 2010, 6:1-2

Published Date: 24 August 2010

Readers of this article also read:

Optimizing stem cell functions and antibacterial properties of TiO2 nanotubes incorporated with ZnO nanoparticles: experiments and modeling

Liu W, Su P, Gonzales III A, Chen S, Wang N, Wang J, Li H, Zhang Z, Webster TJ

International Journal of Nanomedicine 2015, 10:1997-2019

Published Date: 12 March 2015

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Targeting nanomaterials: future drugs for cancer chemotherapy

Zhang Y, Chen T

International Journal of Nanomedicine 2012, 7:5283-5286

Published Date: 10 October 2012

Liposomes and nanotechnology in drug development: focus on oncotargets

Kozako T, Arima N, Yoshimitsu M, Honda S-I, Soeda S

International Journal of Nanomedicine 2012, 7:4943-4951

Published Date: 14 September 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Daanish Hoda, George R Simon, Christopher R Garrett

Therapeutics and Clinical Risk Management 2008, 4:1221-1227

Published Date: 1 September 2008